SP Ventures

SP Ventures is a Sao Paulo-based venture firm that has built one of the strongest agtech and biological sciences franchises in Brazil, with crossover positions in healthcare biotech, pharma adjacencies, and life sciences tools. Check sizes of $1M to $5M are appropriate for seed and Series A participation in capital-intensive biology-driven companies. Healthcare founders should approach SP Ventures with realistic expectations: this is an agtech-rooted fund whose pattern matching is calibrated to plant biology, microbial fermentation, biological inputs, and food systems, with selective expansion into human-health adjacencies.

The firm’s natural fit is with science-rooted founders building at the intersection of biology and human health: microbiome therapeutics, fermentation-derived APIs, novel ingredients for consumer health, biological diagnostics and platforms, and life sciences tools that originated in agricultural research but have human applications. Pure software founders, AI-first models, and digital health platforms are not the right fit. Pre-clinical therapeutics teams looking for ten-year patient capital and FDA-savvy boards will likely find better fits in dedicated biotech funds.

Geographically, Brazil has a credible bench of biological sciences research institutions (Embrapa, USP, UNICAMP) and a large agricultural and pharmaceutical industrial base. SP Ventures’s network into that ecosystem is a real advantage for founders rooted in Brazilian science or building infrastructure for Brazilian and Latin American biological supply chains. For US-only founders without regional ties, the strategic logic is weaker.

The right entry path is via the firm’s agtech network, a regional accelerator with biological science cohorts, or a research institution partner. A cold deck is unlikely to convert without a clear scientific differentiation; the firm reads science seriously. The pitch should lead with the biology, the IP, the development timeline, and an honest regional-to-global commercialization plan. If your asset is human-health-only, explain why the firm’s agriculture-rooted lens is still relevant.

Caveats are meaningful. Most SP Ventures deal flow will be agtech-first; expect partner attention to compete with that pipeline. Brazilian fund structures interact with cross-border venture dynamics in ways that require deliberate corporate structuring; involve a competent regional corporate counsel from the start. The firm’s healthcare-specific track record is selective; do reference calls with portfolio founders before assuming the partnership delivers on human-health-specific needs. For science-rooted founders building at the biology-human-health intersection with Brazilian or Latin American operational ties, SP Ventures is a credible specialty partner; for digital health and AI-first founders, this is not the right fund.